Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Winner

Arena Pharmaceuticals ( ARNA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.7%. By the end of trading, Arena Pharmaceuticals rose 46 cents (6.9%) to $7.08 on heavy volume. Throughout the day, 24.7 million shares of Arena Pharmaceuticals exchanged hands as compared to its average daily volume of 15.3 million shares. The stock ranged in a price between $6.70-$7.23 after having opened the day at $6.75 as compared to the previous trading day's close of $6.62. Other companies within the Drugs industry that increased today were: China Botanic Pharmaceutical ( CBP), up 12.1%, Tengion ( TNGN), up 11.4%, Ampio Pharmaceuticals ( AMPE), up 8.8%, and Pacira Pharmaceuticals ( PCRX), up 7.4%.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. Arena Pharmaceuticals has a market cap of $1.27 billion and is part of the health care sector. Shares are up 235% year to date as of the close of trading on Friday. Currently there are four analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and five rate it a hold.

TheStreet Ratings rates Arena Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been an overall disappointing return on equity.

On the negative front, Cormedix ( CRMD), down 12%, Merrimack Pharmaceuticals ( MACK), down 11.7%, Coronado Biosciences ( CNDO), down 11.2%, and Echo Therapeutics ( ECTE), down 11.1%, were all losers within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null